Daniel J. Lippis Sells 500 Shares of Edwards Lifesciences Co. (NYSE:EW) Stock

Edwards Lifesciences Co. (NYSE:EW) VP Daniel J. Lippis sold 500 shares of the firm’s stock in a transaction on Thursday, January 16th. The stock was sold at an average price of $68.76, for a total value of $34,380.00. Following the transaction, the vice president now directly owns 23,189 shares of the company’s stock, valued at approximately $1,594,475.64. This represents a 2.11 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Edwards Lifesciences Stock Down 0.1 %

EW stock opened at $69.77 on Friday. The company has a quick ratio of 2.89, a current ratio of 3.46 and a debt-to-equity ratio of 0.06. The firm has a market capitalization of $41.15 billion, a PE ratio of 10.07, a P/E/G ratio of 3.77 and a beta of 1.11. The stock’s 50 day moving average is $71.99 and its 200-day moving average is $71.60. Edwards Lifesciences Co. has a twelve month low of $58.93 and a twelve month high of $96.12.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings data on Thursday, October 24th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.67. Edwards Lifesciences had a net margin of 70.82% and a return on equity of 20.76%. The business had revenue of $1.35 billion during the quarter, compared to the consensus estimate of $1.57 billion. During the same period in the prior year, the firm posted $0.59 EPS. The firm’s quarterly revenue was up 8.9% compared to the same quarter last year. Sell-side analysts expect that Edwards Lifesciences Co. will post 2.56 EPS for the current fiscal year.

Analyst Ratings Changes

A number of analysts have weighed in on the stock. Robert W. Baird decreased their target price on shares of Edwards Lifesciences from $73.00 to $68.00 and set a “neutral” rating for the company in a research report on Friday, October 25th. Sanford C. Bernstein raised shares of Edwards Lifesciences from a “strong sell” rating to a “hold” rating in a research note on Monday, October 28th. Morgan Stanley reaffirmed an “equal weight” rating and set a $70.00 price target on shares of Edwards Lifesciences in a research report on Friday, October 11th. Daiwa America lowered Edwards Lifesciences from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, October 30th. Finally, Wolfe Research lowered Edwards Lifesciences from a “peer perform” rating to an “underperform” rating and set a $60.00 target price on the stock. in a research report on Thursday. One research analyst has rated the stock with a sell rating, fifteen have assigned a hold rating and eleven have given a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $78.48.

Institutional Trading of Edwards Lifesciences

A number of hedge funds have recently bought and sold shares of EW. Wellington Management Group LLP grew its holdings in Edwards Lifesciences by 86.3% during the third quarter. Wellington Management Group LLP now owns 31,532,725 shares of the medical research company’s stock valued at $2,080,845,000 after purchasing an additional 14,610,123 shares during the period. State Street Corp lifted its holdings in Edwards Lifesciences by 1.0% during the third quarter. State Street Corp now owns 26,265,633 shares of the medical research company’s stock valued at $1,733,270,000 after purchasing an additional 256,538 shares during the last quarter. Geode Capital Management LLC boosted its position in Edwards Lifesciences by 2.2% during the third quarter. Geode Capital Management LLC now owns 13,521,147 shares of the medical research company’s stock worth $889,050,000 after purchasing an additional 284,918 shares during the period. Fisher Asset Management LLC increased its stake in shares of Edwards Lifesciences by 9.8% in the third quarter. Fisher Asset Management LLC now owns 9,078,311 shares of the medical research company’s stock worth $599,078,000 after purchasing an additional 806,705 shares in the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in shares of Edwards Lifesciences by 1.0% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 6,005,789 shares of the medical research company’s stock valued at $396,322,000 after purchasing an additional 61,275 shares during the period. 79.46% of the stock is currently owned by institutional investors.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.